Xellia Pharmaceuticals ApS

Xellia Pharmaceuticals ApS

About

Company description

Xellia is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases.

Xellia is wholly owned by Novo Holdings A/S.

Production Sites: Five state-of-the-art manufacturing facilities located in; Denmark, Hungary, China and in the U.S.
Expertise: Xellia has over 100 years’ experience in the development, manufacture and supply of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). Xellia is the leading supplier of the important anti-infectives Vancomycin and Colistimethate Sodium (CMS).

Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: Antibiotics |Generic APIs |Finished Dosage Forms More

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 90G10 See our Exhibitor Profile   See full Exhibitor List
9 oct 2018

CPhI Worldwide 2018

9 - 11 October 2018 Madrid, Spain We were at stand 14.0G10 See our Exhibitor Profile   See full Exhibitor List
24 oct 2017

CPhI Worldwide 2017

24 - 26 October 2017 Messe Frankfurt, Germany We were at stand 91C80 See our Exhibitor Profile   See full Exhibitor List

Categories affiliated with Xellia Pharmaceuticals ApS

Xellia Pharmaceuticals ApS

Contact information

Address

Telephone

Website

View all contact information